Trial reportNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Feasibility and safety of vertebrobasilar artery cooling infusion (VACI) following thrombectomy for acute posterior circulation ischemic stroke: A pilot randomized controlled trial.
Trial report in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Not all patients with acute ischemic stroke (AIS) benefit from endovascular therapy (EVT), particularly in the posterior circulation. This pilot randomized controlled trial evaluated the safety, feasibility, and preliminary efficacy of vertebrobasilar artery cooling infusion (VACI) administered after successful recanalization as a neuroprotective strategy for posterior circulation AIS. Participants were randomly assigned (1:1) to VACI or control. The VACI group received 300 mL of 4 °C saline infused into the vertebral artery at 30 mL/min after thrombectomy, whereas controls received 300 mL of 37 °C saline. All patients received standard guideline-based care. The primary endpoint was symptomatic intracranial hemorrhage (sICH). Secondary endpoints included functional outcomes, infarct volume, mortality, intracranial hemorrhage (ICH), vasospasm, coagulation abnormalities, pneumonia, and urinary tract infection. VACI following EVT appears safe and feasible in posterior circulation AIS and may offer potential neuroprotective benefit. Forty patients were enrolled and analyzed. The incidence of sICH did not differ between groups. Rates of neurological deterioration and other complications were comparable. Favorable trends were observed in the VACI group, including improved early neurological recovery (median NIHSS 6 vs. 12.5) and smaller final infarct volume (9.0 vs. 17.5 mL). Mortality was numerically lower in the VACI group at 90 days (10.0% vs. 20.0%) and at 7 days (5.0% vs. 20.0%). Although differences were not statistically significant, outcomes consistently favored VACI. VACI following EVT appears safe and feasible in posterior circulation AIS and may offer potential neuroprotective benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.